Mealey's Patents

  • March 03, 2021

    In Win For Samsung, Federal Circuit Declares Patent Indefinite

    WASHINGTON, D.C. — A stipulation that Samsung Electronics America Inc. and its subsidiaries did not infringe various claims of a patented method of delivering software application packages will not be undone, in view of a decision by the Federal Circuit U.S. Court of Appeals on March 2 to declare the asserted technology invalid.

  • March 03, 2021

    Panel Upholds Sanction For Inventor’s ‘Abusive’ Litigation Misconduct

    WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals on March 1 upheld a decision by a federal judge in Delaware to award various patent infringement defendants their attorney fees as a sanction for a pro se inventor’s baseless allegations.

  • March 01, 2021

    Constitutionality Of Administrative Patent Judges Debated At Supreme Court

    WASHINGTON, D.C. — In oral arguments March 1, a patent owner told the U.S. Supreme Court that the inter partes review (IPR) regime is unconstitutional and that severing Section 3(c) of the Patent Act — which applies the removal restrictions of Title 5 of the U.S. Code, to officers and employees of the U.S. Patent and Trademark Office — “doesn’t solve the problem, because administrative patent judges (APJs) “still have no superior.”

  • March 01, 2021

    Mandamus Bid Rejected By Federal Circuit; Patent Case Will Stay In Texas

    WASHINGTON, D.C. — In a Feb. 25 order, the Federal Circuit U.S. Court of Appeals found no abuse of discretion in a Texas federal judge’s decision to deny allegations that pursuant to the first-to-file rule, transfer of patent infringement claims to California federal court is warranted.

  • February 26, 2021

    Surgical Supplies Firm To High Court: PTAB Judges Are Principal Officers

    WASHINGTON, D.C. — With March 1 oral arguments fast approaching, a surgical supplies manufacturer tells the U.S. Supreme Court in its Feb. 19 reply brief that the administrative patent judges (APJs) of the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (PTO) qualify as principal officers under the appointments clause of the U.S. Constitution and, as such, the rulings in three underlying patent infringement cases should be vacated and remanded to be heard by properly appointed judges.

  • February 26, 2021

    Surgical Firm Seeks End Of Assignor Estoppel Doctrine In Patent Litigation

    WASHINGTON, D.C. — A surgical device company asks the U.S. Supreme Court to eliminate the doctrine of assignor estoppel in its Feb. 22 petitioner merits brief, calling it an “uncommonly lawless doctrine” that has no support in the Patent Act or controlling case law.

  • February 26, 2021

    Targeted Advertising Patent Challenged By Twitter, Google

    ALEXANDRIA, Va. — In a Feb. 24 petition for inter partes review (IPR), Twitter Inc. and Google LLC maintain that the Patent Trial and Appeal Board should cancel 19 claims of a patented method for targeting Internet users with advertisements targeted to computer usage.

  • February 24, 2021

    Maker Of IFit Program Denied Relief In Patent Dispute With Peloton

    WILMINGTON, Del. — A federal judge in Delaware on Feb. 23 rejected a request by ICON Health & Fitness Inc. for a preliminary injunction barring Peloton from selling its new “Bike+” stationary bicycle.

  • February 24, 2021

    Biogen: Reversal Of Collateral Estoppel Ruling Controls New Appeal

    WASHINGTON, D.C. — The maker of the multiple sclerosis (MS) drug Tecfidera in a Feb. 22 appellant brief argues that before deciding whether a federal judge in Delaware erred when ruling that a West Virginia federal judge’s finding of patent invalidity collaterally estops the patent owner from asserting its patent elsewhere, the Federal Circuit U.S. Court of Appeals should first determine whether the collateral estoppel ruling was proper.

  • February 23, 2021

    Appellant: Board Erred In Confirming Sleep Number Patent Valid

    WASHINGTON, D.C. — In a Feb. 18 appellant brief, a manufacturer of sleep surfaces tells the Federal Circuit U.S. Court of Appeals that it should reverse and remand to the Patent Trial and Appeal Board its determination that a patented assembly used to control the pressure in an inflatable mattress and method to inflate the mattress are not obvious.

  • February 23, 2021

    HTC:  Anti-Piracy, BIOS Memory Storage Patent Would Be Obvious

    WASHINGTON, D.C. — In a Feb. 19 petition for inter partes review (IPR), HTC Corp. asserts a claimed method for restricting the unauthorized operation of software by storing a license in the basic input/output system (BIOS) memory of a computer would be obvious to a person of skill in the art.

  • February 23, 2021

    Citing Fintiv, Board Denies Petition For Inter Partes Review

    ALEXANDRIA, Va. — In a Feb. 19 holding, the Patent Trial and Appeal Board turned away a request for inter partes review (IPR) in a dispute over a gaming patent, in view of pending litigation over the same patent in Texas federal court.

  • February 22, 2021

    Patent Claims Covering Fracturing Process Rightly Rejected, Panel Says

    WASHINGTON, D.C. — In a Feb. 19 opinion, the Federal Circuit U.S. Court of Appeals found no error in the Patent Trial and Appeal Board’s affirmance of an examiner’s finding that four claims of a patented process for fracturing the rod that connects the crankshaft to the piston in an internal combustion engine would have been obvious to a person of skill in the art.

  • February 19, 2021

    Patented Myopia Treatment Is Obvious, Petitioner Tells Board

    ALEXANDRIA, Va. — In a Feb. 17 petition for inter partes review (IPR), a pharmaceutical company maintains that the Patent Trial and Appeal Board should cancel 19 claims of a patented myopia treatment featuring increased pH stability via substitution of deuterium oxide (D2O) for regular water (H2O).

  • February 19, 2021

    Mandamus Denied By Panel; Patent Case To Proceed In California

    WASHINGTON, D.C. — In a Feb. 19 order, the Federal Circuit U.S. Court of Appeals turned away a patent owner’s assertion that under the first-to-file rule, it was entitled to dismissal of California federal declaratory judgment actions filed by Apple Inc., AT&T Corp. and Verizon Wireless.

  • February 19, 2021

    Crocs Footwear Patent Properly Confirmed Valid By Board, Panel Says

    WASHINGTON, D.C. — One week after granting an appellant’s motion to substitute itself in a challenge to a Patent Trial and Appeal Board decision that confirmed a Crocs Inc. footwear patent as not anticipated, the Federal Circuit U.S. Court of Appeals on Feb. 18 affirmed the board’s patentability determination on the merits.

  • February 19, 2021

    Panel Directs Board To Reconsider Skin Cancer Patent Holding

    WASHINGTON, D.C. — In a Feb. 18 ruling, the Federal Circuit U.S. Court of Appeals said the Patent Trial and Appeal Board erred in confirming as patentable two independent claims of a patented skin cancer detection, diagnosis and treatment device.

  • February 17, 2021

    Federal Circuit: Patent Board Erred In Refusing To Substitute Challenger

    WASHINGTON, D.C. — In a dispute over a patent covering the ornamental design of footwear, the Federal Circuit U.S. Court of Appeals on Feb. 11 found that transfer of all assets in a bankruptcy proceeding includes the rights in a pending inter partes reexamination (IPR) by the Patent Trial and Appeal Board.

  • February 17, 2021

    Patent Infringement Defendant Covered By Release, Panel Finds

    WASHINGTON, D.C. — In what it described as a case pertaining to the “narrow question of contract interpretation,” a divided Federal Circuit U.S. Court of Appeals on Feb. 11 agreed with a Texas federal judge that a release granted to an entity and its “affiliates” applies to an appellee, thereby barring the grantor of the release from levying claims of patent infringement.

  • February 16, 2021

    Federal Circuit Upholds Rejection Of Obviousness Claim In Patent Row

    WASHINGTON, D.C. — A federal judge in New Jersey did not err in finding that a person of skill in the art would not have enjoyed a reasonable expectation of success in combining various prior art references to arrive at a diabetes inhibitor, the Federal Circuit U.S. Court of Appeals said Feb. 16.

Can't find the article you're looking for? Click here to search the Mealey's Patents archive.